Interferon-γ polymorphism and hepatocellular carcinoma susceptibility: A meta analysis

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 4, 2015, Pages 5667-5674

  Sun, Jing ^a   Liao, Kai ^a   Wang, Yuefei ^a   Zhang, Leida ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Interferon gamma; Polymorphism; Susceptibility

Indexed keywords

GAMMA INTERFERON;

ALLELE; ARTICLE; DNA POLYMORPHISM; GENE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HEPATITIS B; HEPATITIS C; HETEROZYGOTE; HUMAN; LIVER CELL CARCINOMA; META ANALYSIS;

HEPATITIS B VIRUS;

EID: 84935882373     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Boyer N and Marcellin P. Pathogenesis, diagnosis and management of hepatitis C. J Hepatol 2000; 32: 98-112.
3. Rehermann B and Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215-229.
4. Wright TL. Introduction to chronic hepatitis B infection. Am J Gastroenterol 2006; 101 Suppl 1: S1-6.
5. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, Chen PJ, Chen DS and Chen CJ. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-174.
6. Gupta E, Bajpai M and Choudhary A. Hepatitis C virus: Screening, diagnosis, and interpretation of laboratory assays. Asian J Transfus Sci 2014; 8: 19-25.
7. Koziel MJ. Cytokines in viral hepatitis. Semin Liver Dis 1999; 19: 157-169.
8. Sun QL and Ran W. Review of cytokine profiles in patients with hepatitis. World J Gastroenterol 2004; 10: 1709-1715.
9. Huang WS, Cherng SC, Jen TK, Yu MH and Yeh MY. Effects of temperature on radiochemical purity and immunoreactivity of radiolabeled monoclonal antibody 1H10. J Nucl Med Technol 2000; 28: 182-185.
10. Hasday JD, Fairchild KD and Shanholtz C. The role of fever in the infected host. Microbes Infect 2000; 2: 1891-1904.
11. Karalyan Z, Zakaryan H, Sargsyan K, Voskanyan H, Arzumanyan H, Avagyan H and Karalova E. Interferon status and white blood cells during infection with African swine fever virus in vivo. Vet Immunol Immunopathol 2012; 145: 551-555.
12. He YF, Wang XH, Zhang GM, Chen HT, Zhang H and Feng ZH. Sustained low-level expression of interferon-gamma promotes tumor development: potential insights in tumor prevention and tumor immunotherapy. Cancer Immunol Immunother 2005; 54: 891-897.
13. Ruiz-Ruiz C, Munoz-Pinedo C and Lopez-Rivas A. Interferon-gamma treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program. Cancer Res 2000; 60: 5673-5680.
14. Haukim N, Bidwell JL, Smith AJ, Keen LJ, Gallagher G, Kimberly R, Huizinga T, McDermott MF, Oksenberg J, McNicholl J, Pociot F, Hardt C and D’Alfonso S. Cytokine gene polymorphism in human disease: on-line databases, supplement 2. Genes Immun 2002; 3: 313-330.
15. Hollegaard MV and Bidwell JL. Cytokine gene polymorphism in human disease: on-line databases, Supplement 3. Genes Immun 2006; 7: 269-276.
16. Pravica V, Perrey C, Stevens A, Lee JH and Hutchinson IV. A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. Hum Immunol 2000; 61: 863-866.
17. Bouzgarrou N, Hassen E, Farhat K, Bahri O, Gabbouj S, Maamouri N, Ben Mami N, Saffar H, Trabelsi A, Triki H and Chouchane L. Combined analysis of interferon-gamma and interleukin-10 gene polymorphisms and chronic hepatitis C severity. Hum Immunol 2009; 70: 230-236.
18. Migita K, Miyazoe S, Maeda Y, Daikoku M, Abiru S, Ueki T, Yano K, Nagaoka S, Matsumoto T, Nakao K, Hamasaki K, Yatsuhashi H, Ishibashi H and Eguchi K. Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection--association between TGF-beta1 polymorphisms and hepatocellular carcinoma. J Hepatol 2005; 42: 505-510.
19. Nieters A, Yuan JM, Sun CL, Zhang ZQ, Stoehlmacher J, Govindarajan S and Yu MC. Effect of cytokine genotypes on the hepatitis B virus-hepatocellular carcinoma association. Cancer 2005; 103: 740-748.
20. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603-605.
21. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA and Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012.
22. Mantel N and Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
23. DerSimonian R and Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
24. Egger M, Davey Smith G, Schneider M and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
25. Ben-Ari Z, Mor E, Papo O, Kfir B, Sulkes J, Tambur AR, Tur-Kaspa R and Klein T. Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol 2003; 98: 144-150.
26. Saxena R, Chawla YK, Verma I and Kaur J. IFN-gamma (+874) and not TNF-alpha (-308) is associated with HBV-HCC risk in India. Mol Cell Biochem 2014; 385: 297-307.
27. Teixeira AC, Mendes CT Jr, Marano LA, Deghaide NH, Secaf M, Elias J Jr, Muglia V, Donadi EA, Martinelli AL. Alleles and genotypes of polymorphisms of IL-18, TNF-alpha and IFN-gamma are associated with a higher risk and severity of hepatocellular carcinoma (HCC) in Brazil. Hum Immunol 2013; 74: 1024-1029.
28. Liu F, Li B, Wei YG, Chen X, Ma Y, Yan LN, Wen TF, Xu MQ, Wang WT and Yang JY. IFN-gamma+874 A/T polymorphism and cancer risk: an updated analysis based on 32 case-control studies. Cytokine 2011; 56: 200-207.
29. Ge YZ, Wang YD, Xu Z, Xu LW, Wang YP, Gu MH, Ding AX, Zhu XB, Wu R, Li WC, Xu YD and Jia RP. Lack of association between interferon gamma +874 T/A polymorphism and cancer risk: an updated meta-analysis. Tumour Biol 2014; 35: 6405-6414.
30. Schroder K, Hertzog PJ, Ravasi T and Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004; 75: 163-189.
31. Billiau A and Matthys P. Interferon-gamma: a historical perspective. Cytokine Growth Factor Rev 2009; 20: 97-113.
32. Schoenborn JR and Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 2007; 96: 41-101.
33. Zaidi MR and Merlino G. The two faces of interferon-gamma in cancer. Clin Cancer Res 2011; 17: 6118-6124.
34. Isaacs A and Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957; 147: 258-267.
35. Nakashima H, Miyake K, Clark CR, Bekisz J, Finbloom J, Husain SR, Baron S, Puri RK and Zoon KC. Potent antitumor effects of combination therapy with IFNs and monocytes in mouse models of established human ovarian and melanoma tumors. Cancer Immunol Immunother 2012; 61: 1081-1092.
36. Bekisz J, Sato Y, Johnson C, Husain SR, Puri RK and Zoon KC. Immunomodulatory effects of interferons in malignancies. J Interferon Cytokine Res 2013; 33: 154-161.
37. Li Q, Du J, Guan P, Qu CF and Dai M. [Estimation and prediction of incidence, mortality and prevalence on liver cancer, in 2008, China]. Zhonghua Liu Xing Bing Xue Za Zhi 2012; 33: 554-557.
38. El-Serag HB and Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576.